Research may help rescue antibiotics' effectiveness in the face of drug-resistant bacteria

August 10, 2018, Beth Israel Deaconess Medical Center

Bacteria—especially Gram-negative strains—are becoming increasingly resistant to current antibiotic drugs, and the development of new classes of antibiotics has slowed. Faced with these challenges, investigators are studying the potential of combination therapy, in which two or more drugs are used together to increase or restore the efficacy of both drugs against a resistant bacterial pathogen. Now new research indicates that such synergy may work even when bacteria become resistant to colistin, which is considered a treatment agent of last resort.

The findings are especially promising because recent evidence indicates the potential for rapid worldwide spread of colistin resistance. "For an infected patient, if the multidrug-resistant Gram-negative bacterial pathogen is resistant to colistin, then there is a big problem," said senior author James Kirby, MD, Director of the Clinical Microbiology Laboratory at BIDMC.

In their Antimicrobial Agents and Chemotherapy study, Kirby and his colleagues Thea Brennan-Krohn, MD and Alejandro Pironti, Ph.D. screened 19 different for synergy with colistin. The team discovered several combinations where synergy was present and infections with could potentially be treated with the .

Of particular interest, colistin demonstrated high rates of synergy with linezolid, fusidic acid, and clindamycin, which are protein synthesis inhibitor antibiotics that individually have no activity against Gram-negative bacteria. "It was remarkable to see two drugs, each of which is inactive on its own against these bacteria, inhibiting them in combination," notes Brennan-Krohn. "These findings suggest that colistin retains sub-lethal activity against colistin-resistant bacteria, which may enable drugs like linezolid to reach their targets."

"Faced with highly resistant pathogens, clinicians often currently treat with multiple antibiotics without knowing the benefit the combinations may provide," said Kirby. "This study now provides some scientific underpinning for these choices and direction for future investigation." He added that combination therapy may also allow clinicians to use lower effective doses of and other drugs, which would help avoid toxicities associated with the medications as well as slow the development of antibiotic resistance.

Explore further: Colistin-resistant multidrug-resistant bacteria pervasive in rural Vietnam town

Related Stories

Colistin-resistant multidrug-resistant bacteria pervasive in rural Vietnam town

June 9, 2018
A new study has found that the majority of residents in a rural village of Vietnam harbored multi-drug-resistant (MDR), colistin-resistant E. coli bacteria. Colistin is typically used as a last-resort treatment when there ...

New resistance mechanism in the often multidrug resistant pathogen Acinetobacter baumannii

April 30, 2018
A team of Australian and Portuguese investigators has discovered yet another resistance mechanism in the pathogen, Acinetobacter baumannii, in this case, one that blocks the critical antibiotic-of-last-resort, colistin. A. ...

Even short travel can spread colistin-resistant bacteria

April 12, 2018
The emergence of antibiotic resistance among dangerous pathogens is increasingly problematic worldwide. Many strains of infectious bacteria have become multidrug-resistant, and cannot be treated with common antibiotic therapies. ...

Bacteria resistant to last-resort antibiotic, missed by standard tests

March 6, 2018
Emory microbiologists have detected "heteroresistance" to colistin, a last-resort antibiotic, in already highly resistant Klebsiella pneumoniae, a bacterium that causes blood, soft tissue and urinary tract infections.

Researchers discover novel colistin resistance gene mcr-3 in Escherichia coli

June 27, 2017
Researchers have now discovered a new mobile colistin resistance gene, mcr-3, in E. coli of pig origin. The novel mcr-3 gene was discovered when a colistin-resistant Escherichia coli isolate tested negative for both mcr-1 ...

Recommended for you

Collaboration yields possible treatment for rare neurodegenerative disorder

October 23, 2018
St. Jude Children's Research Hospital investigators have developed a new class of compounds that extended the lives and eased symptoms of mice with a progressive neurodegenerative human disorder. The findings appear today ...

'Game changer' tuberculosis drug cures 9 in 10

October 22, 2018
A new treatment for a drug-resistant strain of tuberculosis can cure more than 90 percent of sufferers, according to a trial hailed Monday as a "game changer" in the fight against the global killer.

AI doctor could boost chance of survival for sepsis patients

October 22, 2018
Scientists have created an artificial intelligence system that could help treat patients with sepsis.

A guide to Acute flaccid myelitis (AFM), the rare, polio-like illness making young children sick

October 22, 2018
A fast-acting, polio-like illness has sickened 62 young children, with an average age of 4, in 22 U.S. states so far this fall.

Scientists in Sweden may have figured out one way acne bacteria defies treatment

October 22, 2018
Researchers in Sweden have discovered how acne-causing bacteria feed off their human hosts. The study, which was performed at KTH Royal Institute of Technology, could make it possible to find effective ways to treat severe ...

Consuming caffeine from coffee reduces incident rosacea

October 22, 2018
(HealthDay)—Caffeine intake from coffee is inversely associated with the risk for incident rosacea, according to a study published online Oct. 17 in JAMA Dermatology.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.